Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 - 65 years of age~* Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to screening~* Currently receiving treatment with a low to medium dose of an inhaled corticosteroid (ICS) OR a combination of controller medications for at least 4 weeks preceding screening~* Pre-albuterol FEV1 of \> 60% and \< 85% of predicted normal value~* Reversibility: Increase in FEV1 of ≥ 12% and ≥ 200 mL over the pre-albuterol FEV1 within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin hydrofluoroalkane (HFA)~* Asthma Symptom Criteria: Have required albuterol use on at least two of the last seven days and have an Asthma Control Questionnaire (ACQ) total score ≥ 1.5 prior to Randomization~Exclusion Criteria:~* Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening~* Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an emergency department visit, hospitalization or use of oral/parenteral corticosteroids within 6 weeks of screening~* Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only intermittent, seasonal or exercise-induced asthma are excluded from participation in this study~* Concurrent Respiratory Disease~* Pregnant women or nursing mothers~* A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD~* Current smokers or subjects with a \> 10 pack year history of cigarettes, cigars, or pipe smoking~* Respiratory tract infection within 6 weeks prior to Visit 1~* Subjects with documented myocardial infarction within a year from screening visit~* Clinically significant abnormal ECG~* Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥ 1.5 times upper limit of normal on repeat testing~* Subjects who have cancer that has not been in complete remission for at least 5 years~* Drug Allergy: Subjects who have a history of hypersensitivity to any component of the metered-dose inhaler (MDI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BD MDI 320 µg (Type: EXPERIMENTAL): Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
- BD MDI 160 µg (Type: EXPERIMENTAL): BD MDI 160 µg (PT008) administered as 2 inhalations BID
- BD MDI 80 µg (Type: EXPERIMENTAL): BD MDI 80 µg (PT008) administered as 2 inhalations BID
- BD MDI 40 µg (Type: EXPERIMENTAL): BD MDI 40 µg (PT008) administered as 2 inhalations BID
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo MDI administered as 2 inhalations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).